Trial Profile
Safety and efficacy of 2-weekly cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who were treated previously with docetaxel.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2017
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Mar 2017 Results (n=43) published in the BJU International
- 10 Aug 2015 New trial record